Search for: "KING PHARMACEUTICALS V EON LABS" Results 1 - 17 of 17
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
12 Aug 2010, 9:57 pm by Patent Docs
By Andrew Williams -- Last week, in King Pharmaceuticals, Inc. v. [read post]
23 Feb 2009, 9:59 pm
By Suresh Pillai --King Pharmaceuticals' Patents on SKELAXIN ® Invalidated By District Court In the case of King Pharmaceuticals, Inc. v. [read post]
10 Aug 2010, 8:44 pm by Marie Louise
  Highlights this week included: CAFC: Genus-species; doctrine of equivalents; and patentable subject matter: Intervet v Merial Limited (Patently-O) (Holman’s Biotech IP Blog) (IP Spotlight) (IPBiz) (Patent Docs) Angiomax (Bivalirudin) – US: The Medicines Company prevails in patent term extension dispute; USPTO acts quickly to comply with court order (Patent Docs) (Patent Docs) (IPBiz) Skelaxin (Metaxalone) – US: CAFC: Ignoring non-patentable elements while judging… [read post]
23 Jan 2009, 12:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: India: Discussion of Delhi High Court Dasatinib order – patent linkage between Indian Patent Office and Office of the Drug Controller General of India (Patent Circle) (Spicy IP) (Patent Circle) (Managing Intellectual Property) Lescol (Fluvastatin) – US: EWHC finds sustained release Fluvastatin patent invalid on ground of… [read post]
1 Sep 2010, 4:46 pm by Dennis Crouch
Eon Labs, Inc. and Elan Pharmaceuticals, Inc. at http://www.patentlyo.com/patent/2010/08/ignoring-non-patentable-elements-while-judging-novelty.html Hyatt v. [read post]
30 Jan 2009, 9:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: US: AIPLA urges Federal Circuit not to proscribe patents for biomedical diagnostic tools: Prometheus v Mayo (Inventive Step) (Hal Wegner) (Patently-O) (Holman's Biotech IP Blog) Lovenox (Enoxaparin) – US: Aventis files for certiorari: challenging Federal Circuit’s low standard for intent to deceive in… [read post]